Memorial Sloan-Kettering
Myriad Genetics, Memorial Sloan Kettering Partner to Study MRD Testing in Breast Cancer
The collaborators will evaluate the use of Myriad's MRD platform in predicting response to CDK4/6 inhibitors and in a chemotherapy neoadjuvant setting.
At AACR, the company highlighted new prospective and retrospective data that it believes helps set its platform apart from other available ctDNA technologies.
Sophia Genetics to Commercialize MSK-ACCESS Clinical Liquid Biopsy Test
The collaboration between Sophia and Memorial Sloan Kettering Cancer Center aims to offer new testing and analytics capabilities to clinicians and researchers.
NewStem, MSK Innovation Hub Team to Validate Cancer Diagnostics Software Platform
The Israeli startup called this collaboration a necessary step toward commercializing its CE-marked NewStem Software Diagnostic Device for reducing oncology drug resistance.
Sophia Genetics Partners With MSK on Clinical Decision Support, Boundless Bio on ecDNA Detection
Sophia will provide Memorial Sloan Kettering with predictive tumor analysis technology and help startup Boundless develop new therapies and MDx methods.